Joost H. van den Berg

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg et al. · New England Journal of Medicine · 2022 · 474 citations · Full text

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

Meike E. W. Logtenberg, J.H. Marco Jansen, Matthijs Raaben et al. · Nature Medicine · 2019 · 235 citations

Cancer Immunosurveillance, Medicine, Immunology +6

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

Joost H. van den Berg, Bianca Heemskerk, Nienke van Rooij et al. · Journal for ImmunoTherapy of Cancer · 2020 · 184 citations · Full text

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor

Joost H. van den Berg, Raquel Gomez-Eerland, B. van de Wiel et al. · Molecular Therapy · 2015 · 106 citations · Full text

Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity

Joost H. van den Berg, Koen Oosterhuis, Wim E. Hennink et al. · Journal of Controlled Release · 2009 · 73 citations

Nanoparticles, Nanomedicine, Cross-protection +11